Why the study?
Data are limited on the effect of beta-blockers on the incidence of periprocedural myocardial injury after elective PCI.
Does β-blocker use before elective PCI affect the incidence of periprocedural myocardial injury in patients undergoing elective PCI?
Does β-blocker use before elective PCI affect the incidence of periprocedural myocardial injury in patients undergoing elective PCI?
Pre-procedural β-blocker use is associated with an increased risk of periprocedural myocardial injury in male patients under 75 years old undergoing elective PCI.
Answers are grounded in this paper and cite their sources.
Prior β-blocker use was associated with higher PMI risk in men <75 years; leaves open causal effect and need for randomized confirmation before practice change.
BACKGROUND: β-blockers are indicated in several cardiovascular diseases. However, data are limited on their effect on the periprocedural myocardial injury (PMI) incidence. This study was designed to evaluate the impact of using β-blockers before elective percutaneous coronary intervention (PCI) on PMI incidence. METHODS: This study included 4,027 patients who underwent elective PCI and had no elevated serum troponin I (TnI) or creatine kinase-MB (CK-MB) levels before PCI. Patients were divided into four groups based on gender and age (cut-off point 75 years). Serum TnI and CK-MB levels were measured before and every eight hours after the procedure. PMI was defined as postprocedural TnI or CK-MB ≥5 times the upper limits of normal (ULN) values. Logistic regression analysis including factors such as age, sex, prior β-blocker therapy, previous MI, length of implanted stents, characteristics of lesion and so on was performed to assess the effects of prior β-blocker therapy on the incidence of PMI. RESULTS: In 2,332 male patients <75 years old, PMI incidence was higher in the β-blocker pre-usage subgroup than the no β-blocker pre-usage subgroup (16.4% vs. 11.7%, respectively; P=0.001). For the female patients ≥75 years old, the β-blocker pre-usage subgroup had a lower PMI incidence compared with the no β-blocker pre-usage subgroup (18.2% vs. 31.7%, respectively; P=0.012). In logistic regression analysis, the total length of implanted stents was a risk factor for PMI incidence in all patients. Also, β-blocker pre-usage was an independent risk factor for PMI in male patients <75 years old (HR =1.424, 95% CI: 1.088-1.864; P=0.01). However, we did not observe a significant effect in female patients ≥75 years old. CONCLUSIONS: Our study indicates that the PCI-PMI association depends on age and gender groups, β-blocker use before PCI is associated with increased PMI incidence in male patients <75 years old.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: